A study in women with overweight or obesity to test whether different doses of BI 456906 influence the amount of a contraceptive in the blood

2022-503146-53-00 Protocol 1404-0014 Human pharmacology (Phase I) - Other Ended

Start 7 Dec 2023 · End 26 Mar 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 1404-0014

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 24
Countries 1
Sites 1

pharmacokinetic trial

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
7 Dec 2023 → 26 Mar 2025
Decision date (initial)
2023-08-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2022-503146-53-00
WHO UTN
U1111-1288-9112

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

pharmacokinetic trial

VersionLevelCodeTermSystem organ class
21.0 LLT 10053349 Pharmacokinetic study 10022891

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 24 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Charite Research Organisation GmbH
Charité Universitätsmedizin Berlin, Chariteplatz 1, Mitte, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2023-12-07 2025-03-26 2023-12-21 2024-06-27

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-06-20 Germany Acceptable
2023-08-14
2023-08-16
2 SUBSTANTIAL MODIFICATION SM-1 2023-10-18 Germany Acceptable
2023-11-13
2023-11-15
3 SUBSTANTIAL MODIFICATION SM-2 2024-06-20 Germany Acceptable
2024-07-12
2024-07-18
4 NON SUBSTANTIAL MODIFICATION NSM-1 2025-02-26 Germany Acceptable
2024-07-12
2025-02-26